Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial.

ABSTRACT:

Background

Variation in de-adoption of ineffective or unsafe treatments is not well-understood. We examined de-adoption of erythropoiesis-stimulating agents (ESA) in anemia treatment among patients with chronic kidney disease (CKD) following new clinical evidence of harm and ineffectiveness (the TREAT trial) and the FDA's revision of its safety warning.

Method

We used a segmented regression approach to estimate changes in use of epoetin alfa (EPO) and darbepoetin alfa (DPO) in the commercial, Medicare Advantage (MA) and Medicare fee-for-service (FFS) populations. We also examined how changes in both trends and levels of use were associated with physicians' characteristics.

Results

Use of DPO and EPO declined over the study period. There were no consistent changes in D

SUBMITTER: Vu K 

PROVIDER: S-EPMC8379779 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature